Results 11 to 20 of about 57,560 (274)

Clarithromycin-based Helicobacter pylori eradication therapy is not associated with higher treatment failure compared with non-clarithromycin-based regimens in a tertiary referral hospital in Switzerland [PDF]

Swiss Medical Weekly, 2023
BACKGROUND AND AIMS: Due to increasing antibiotic resistance, various Helicobacter pylori eradication regimens other than clarithromycin-based therapies have been proposed.
Tobias Braendli, Valeria Schindler, Dominique Laurent Braun, Fritz R. Murray, Juliane Marie Hente, Daniel Pohl   +5 more
doaj   +2 more sources

Clarithromycin Resistance in Helicobacter Pylori

Central Asian Journal of Medical Sciences, 2016
Objectives: Eradication rates of Helicobacter pylori with standard triple therapy are disappointing in studies from several countries. The main reason for failure was found to be bacterial resistance to one of the most commonly used antibiotics ...
Mandkhai Bolor-Erdene, Bira Namdag, Sarantuya Jav   +2 more
doaj   +3 more sources

Efflux Pumps Contribute to Intrinsic Clarithromycin Resistance in Clinical, Mycobacterium abscessus Isolates

Infection and Drug Resistance, 2020
Qi Guo,1,2 Jianhui Chen,1,2 Shaoyan Zhang,1 Yuzhen Zou,1,2 Yongjie Zhang,1,2 Dongdong Huang,1 Zhemin Zhang,1 Bing Li,1 Haiqing Chu1,3 1Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433,
Guo Q, Chen J, Zhang S, Zou Y, Zhang Y, Huang D, Zhang Z, Li B, Chu H   +8 more
doaj   +2 more sources

Detection of antimicrobial resistance genes of Helicobacter pylori strains to clarithromycin, metronidazole, amoxicillin and tetracycline among Egyptian patients

Egyptian Journal of Medical Human Genetics, 2018
Background: Antibiotic resistance of Helicobacter pylori (H. pylori) treatment is on the rise, and is affecting the efficacy of current used therapeutic regimens. Aim: We aimed to enhance the understanding of antimicrobial resistance rates of H.
Manal Diab, Ahmed El-Shenawy, Maged El-Ghannam, Dalia Salem, Moustafa Abdelnasser, Mohamed Shaheen, Mahmoud Abdel-Hady, Effat El-Sherbini, Mohamed Saber   +8 more
doaj   +2 more sources

Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial

Critical Care, 2022
Background Clarithromycin may act as immune-regulating treatment in sepsis and acute respiratory dysfunction syndrome. However, clinical evidence remains inconclusive.
E. Karakike, B. Scicluna, Maria Roumpoutsou, Ioannis Mitrou, Niki Karampela, A. Karageorgos, K. Psaroulis, E. Massa, A. Pitsoulis, Panagiotis Chaloulis, E. Pappa, Irene T. Schrijver, F. Frantzeskaki, M. Lada, N. Dauby, D. De Bels, I. Floros, Souzana Anisoglou, E. Antoniadou, M. Patrani, Glykeria Vlachogianni, E. Mouloudi, A. Antoniadou, D. Grimaldi, T. Roger, W. Wiersinga, I. Tsangaris, E. Giamarellos‐Bourboulis   +27 more
semanticscholar   +1 more source

Clarithromycin Solid Lipid Nanoparticles for Topical Ocular Therapy: Optimization, Evaluation, and In Vivo Studies

Pharmaceutics, 2021
Solid lipid nanoparticles (SLNs) are being extensively exploited as topical ocular carrier systems to enhance the bioavailability of drugs. This study investigated the prospects of drug-loaded SLNs to increase the ocular permeation and improve the ...
Anroop B Nair, Jigar N. Shah, Bandar E Al-dhubiab, S. Jacob, Snehal S. Patel, Katharigatta N. Venugopala, M. Morsy, Sumeet Gupta, M. Attimarad, N. Sreeharsha, P. Shinu   +10 more
semanticscholar   +1 more source

Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides

Nature Communications, 2021
Clarithromycin is a macrolide antibiotic widely used for eradication of Helicobacter pylori infection, and thus resistance to this antibiotic is a major cause of treatment failure.
Éva Kocsmár, G. Buzás, I. Szirtes, I. Kocsmár, Zsófia Kramer, A. Szíjártó, P. Fadgyas-Freyler, K. Szénás, M. Rugge, M. Fassan, A. Kiss, Z. Schaff, G. Röst, G. Lotz   +13 more
semanticscholar   +1 more source

Susceptibility-Guided Versus Empirical Therapy for Helicobacter pylori Infection in a High Resistance Setting: A Randomised Controlled Trial. [PDF]

Microbiologyopen
In a randomised trial conducted in a high‐resistance region, PCR‐based susceptibility‐guided therapy showed no superiority over empirical therapy for Helicobacter pylori eradication. Empirical clarithromycin‐containing quadruple therapy remained effective despite high clarithromycin resistance.
Lu K, Zou X, Lang C, Zang L, Yang X, Sang W, Wang J, Feng Q, Mu Y, Liu L, Xu C, Zhao J.   +11 more
europepmc   +2 more sources

Detection of clarithromycin resistance and 23SrRNA point mutations in clinical isolates of Helicobacter pylori isolates: Phenotypic and molecular methods

Saudi Journal of Biological Sciences, 2021
Background and objectives Peptic ulcer disease, chronic gastritis, and stomach cancer are all caused by H. pylori. The most notable drug for the treatment is the antibiotic clarithromycin, which is currently the drug of choice. H.
Rawaa A. Hussein, Mushtak T. S. Al-Ouqaili, Y. Majeed   +2 more
semanticscholar   +1 more source

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for Helicobacter pylori infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

BMJ Open, 2023
Introduction Helicobacter pylori is the most well-known risk factor for gastric cancer. Antibiotic resistance is the main reason for the failure of H.
Yan Li, Hao Wu, Jun Ye, Yujing Wang, Oulan Liao, Yaoyi Wu, Qin Du, Xiaochen Liu, Guochun Lou   +8 more
doaj   +1 more source